CPRX Share Price Performance
US$23.28
2.09 (9.86%)
32.1% undervalued intrinsic discount
US$34.29
Fair Value
Price US$23.28
AnalystConsensusTarget US$34.29
Fair ValueUS$34.29
Share Pricen/a
Catalyst Pharmaceuticals, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 116 Fair Values set on narratives written by author
CPRX Community Narratives
AN
Fair Value US$34.29 32.1% undervalued intrinsic discount
Updated NCCN Guidelines Will Expand Rare Disease Diagnosis
1users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
Updated NCCN Guidelines Will Expand Rare Disease Diagnosis
Key Takeaways Expansion of diagnoses and payer coverage is driving broader patient access and sustained high revenue growth across Catalyst's rare disease portfolio. Strong product launches, durable margins, and disciplined business development position Catalyst for continued earnings growth amid increasing competition.Read more
1users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
AN
US$34.29
32.1% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
8.29% p.a.
Profit Margin
35.75%
Future PE
21.73x
Share price in 2028
US$41.66
Recently Updated Narratives
AN
Updated NCCN Guidelines Will Expand Rare Disease Diagnosis
Fair Value: US$34.29 32.1% undervalued intrinsic discount
52 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Catalyst Pharmaceuticals, Inc. Key Details
About CPRX
- Founded
- 2002
- Employees
- 181
- CEO
- WebsiteView website
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
